Company Aggregate Debt: bioAffinity Technologies Inc. (BIAF)

bioAffinity Technologies develops patented non-contact lung tumor detection methods, utilizing neural networks for cell analysis. The CyPath Lung technology ensures precision results without invasive intervention. However, the implementation stage of CyPath360 and the lack of insurance reimbursements keep service costs at 0.00. The asset's price history on GURU.Markets clearly demonstrates market expectations for this medical business.

To assess the fundamental stability of bioAffinity Technologies (BIAF), investors must analyze the aggregate borrowed liabilities that determine the capital structure and financial risks. The current level of accounts payable stands at 0.00, reflecting the volume of funds raised to scale unique lung cancer diagnostic tests and integrate them into standard oncological screening protocols.